Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

This trial is testing a specialized cell therapy called mipetresgene autoleucel (Mip-cel) — engineered immune cells that are trained to recognize and attack a protein called NY-ESO-1 found on synovial sarcoma cells — in patients whose cancer has returned or stopped responding to chemotherapy. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of synovial sarcoma (a type of soft tissue cancer) - Your tumor cannot be surgically removed - Your cancer is recurring or progressing after 1 to 4 prior chemotherapy regimens (including anthracycline-based chemotherapy) - Your tumor tests positive for NY-ESO-1 protein and you have a specific immune marker (HLA-A*02:01 or HLA-A*02:06) - Your organ function is in an acceptable range **You may NOT be eligible if...** - You have active heart problems (e.g., recent heart attack or unstable angina) - You have serious infections or active autoimmune disease - You have received another investigational treatment recently Talk to your doctor to see if this trial is right for you.